Compounded GLP-1 Vial vs Brand-Name Pen: Key Differences

Brand-name GLP-1 pens like Ozempic, Wegovy, Mounjaro, and Zepbound come pre-filled with a fixed concentration and have a built-in dose selector. You dial your prescribed dose on the pen, press the button, and inject. There is no calculation or measurement required.

Compounded GLP-1 vials contain the same active ingredient (semaglutide or tirzepatide) but require you to draw the medication using a U-100 insulin syringe. You must calculate how many units to draw based on your prescribed dose and the vial's concentration using the formula: units = (dose in mg / concentration in mg per mL) x 100. This adds a manual step but gives providers more flexibility in prescribing exact doses.

Cost is the most significant difference for many patients. Brand-name GLP-1 pens carry list prices of $900 to $1,350 per month without insurance. Even with insurance coverage, copays can be $25 to $500 per month depending on the plan and formulary tier.

Compounded GLP-1 medications are substantially less expensive, typically ranging from $200 to $500 per month. The lower cost is possible because compounding pharmacies produce the medication using bulk active pharmaceutical ingredients rather than selling a branded product. For patients without insurance coverage for weight management medications, the savings can be $600 to $1,000 per month.

Brand-name GLP-1 medications have experienced intermittent supply shortages since 2022, particularly Ozempic and Mounjaro. During shortages, patients may be unable to fill their prescriptions for weeks at a time, causing treatment interruptions.

Compounded medications have generally maintained better availability because multiple licensed pharmacies can produce them independently. The FDA permits compounding of medications during declared shortages. However, if and when shortages are resolved and the FDA revokes shortage designations, some compounded versions may face regulatory changes. Patients should stay informed about the current status of their medication.

Brand-name pens are FDA-approved products manufactured under strict Current Good Manufacturing Practice (cGMP) regulations. Each batch undergoes testing for potency, purity, and sterility before reaching patients.

Compounded GLP-1 medications are not FDA-approved as finished products. They are prepared by licensed compounding pharmacies under two frameworks: 503A pharmacies (state-licensed, patient-specific prescriptions) and 503B outsourcing facilities (FDA-registered, can produce larger batches). The 503B designation comes with more rigorous oversight, including FDA inspections and reporting requirements. Your provider should source from pharmacies with strong quality track records.

Brand-name pens win on convenience. There is no dose calculation, no syringe selection, and no drawing technique to learn. The pen is ready to use out of the box. This simplicity reduces the chance of dosing errors.

Compounded vials offer more dosing flexibility. Providers can prescribe any milligram dose within the available concentration range, rather than being limited to the fixed dose increments on a pen. This is particularly useful during dose escalation, where a provider might want to prescribe a dose between standard pen increments. Vials also allow for more gradual titration if a patient experiences side effects.

Both options deliver the same medication subcutaneously. The best choice depends on your budget, insurance coverage, provider recommendation, and comfort with dose preparation. Discuss the options with your healthcare provider.